ARTICLE | Clinical News
CEE 03-310: Began Phase II trial
March 5, 2001 8:00 AM UTC
CeNeS Pharmaceuticals plc (LSE:CEN), Cambridge, U.K. Product: CEE 03-310 Business: Neurological Therapeutic category: Neurotransmission, Receptor antagonist Target: Dopamine D1 receptors Description: ...